Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charite Campus Berlin Mitte
-
Göppingen, Germany, 73035
- Klinik am Eichert
-
Leverkusen, Germany, 51379
- St. Remigius Krankenhaus Opladen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Minimum age 18 years
- Indication for cementless hip arthroplasty with acetabular defects that need Allograft or titanium augment
- Patient consent for study participation
- Physical and mental willingness to participate in the follow-ups
Exclusion Criteria:
- Patient not available for follow-up
- Increased anesthetics risks for the patient according to the "American Society of Anesthesiology": ASA IV
- Tumor
- Alcohol- or Drug abuse
- Permanent cortisone therapy
- Clinically relevant infection
- (Planned) pregnancy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Structan®
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Survival Rates
Time Frame: 12 months
|
Implant survival is analysed at follow-up examinations at 3 and 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Outcome
Time Frame: 3 and 12 months
|
Harris Hip Score
|
3 and 12 months
|
|
Pain
Time Frame: 3 and 12 months
|
Visual Analogue Scale (VAS)
|
3 and 12 months
|
|
Osteolysis
Time Frame: 3 and 12 months
|
Radiographic Outcome
|
3 and 12 months
|
|
Ossifications
Time Frame: 3 and 12 months
|
Radiographic Outcome
|
3 and 12 months
|
|
Implant Position
Time Frame: 3 and 12 months
|
Radiographic Outcome
|
3 and 12 months
|
|
Migration of Structan®
Time Frame: 3 and 12 months
|
Radiographic Outcome
|
3 and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- AAG-O-H-1212
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.